NCT05509699View on ClinicalTrials.gov

Surufatinib Plus Anti-PD-1/L1 as Maintenance Therapy in Extensive-Stage Small Cell Lung Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

September 27, 2022

Primary Completion Date

July 31, 2024

Study Completion Date

July 31, 2024

Conditions
Extensive-Stage Small Cell Lung Cancer
Interventions
DRUG

Surufatinib

The recommended dosage is 250 mg orally once daily (QD) within 1 hour after breakfast for continuous administration.

DRUG

Anti-PD-1/L1

Anti-PD-1/L1 therapy, Q3W or Q4W, the same immune checkpoint inhibitor from patients' first-line therapy.

Trial Locations (1)

Unknown

Chinese PLA General Hospital, Beijing

All Listed Sponsors
lead

Hutchison Medipharma Limited

INDUSTRY